| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5647129 | Journal of Allergy and Clinical Immunology | 2017 | 31 Pages |
Abstract
In this first placebo-controlled study, canakinumab was effective in patients with Schnitzler syndrome, and thus canakinumab may be further evaluated as a therapeutic option for this rare disease.
Keywords
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Karoline MD, Athanasios MD, Nicola MD, Jörg MD, Karsten MD, Martin MD, Martin K. PhD, Marcus MD,